These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 27416313)
1. Isotretinoin for acne and rosacea. Watson KD; Miest RY; Tollefson MM Semin Cutan Med Surg; 2016 Jun; 35(2):79-86. PubMed ID: 27416313 [TBL] [Abstract][Full Text] [Related]
2. What's new in acne and rosacea? Keri J Semin Cutan Med Surg; 2016 Jun; 35(2):103-6. PubMed ID: 27416316 [TBL] [Abstract][Full Text] [Related]
3. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Rademaker M Australas J Dermatol; 2013 Aug; 54(3):157-62. PubMed ID: 23013115 [TBL] [Abstract][Full Text] [Related]
5. The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies. Rigopoulos D; Larios G; Katsambas AD Clin Dermatol; 2010; 28(1):24-30. PubMed ID: 20082946 [TBL] [Abstract][Full Text] [Related]
6. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. Blasiak RC; Stamey CR; Burkhart CN; Lugo-Somolinos A; Morrell DS JAMA Dermatol; 2013 Dec; 149(12):1392-8. PubMed ID: 24173086 [TBL] [Abstract][Full Text] [Related]
7. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Layton AM; Dréno B; Gollnick H; Mobaken H; Shear N Br J Dermatol; 2009 Jan; 160(1):217-8; author reply 218-9. PubMed ID: 19067687 [No Abstract] [Full Text] [Related]
8. On isotretinoin dosing, adverse effects, and efficacy. Berk DR Australas J Dermatol; 2011 May; 52(2):147-8; author reply 148. PubMed ID: 21605103 [No Abstract] [Full Text] [Related]
9. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Cyrulnik AA; Viola KV; Gewirtzman AJ; Cohen SR Int J Dermatol; 2012 Sep; 51(9):1123-30. PubMed ID: 22909370 [TBL] [Abstract][Full Text] [Related]
11. Treatment of extrafacial rosacea with low-dose isotretinoin. Bostanci O; Borelli C; Schaller M Acta Derm Venereol; 2010 Jul; 90(4):409-10. PubMed ID: 20574608 [No Abstract] [Full Text] [Related]
12. Is oral isotretinoin the treatment of choice in moderate and severe inflammatory acne vulgaris? Verros CD; Rallis E J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1270-1. PubMed ID: 17894728 [No Abstract] [Full Text] [Related]
13. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin. Ahmad HM Dermatol Ther; 2015; 28(3):151-7. PubMed ID: 25754162 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris. Boyraz N; Mustak PK Int J Dermatol; 2013 Oct; 52(10):1265-7. PubMed ID: 23675954 [TBL] [Abstract][Full Text] [Related]
15. Dermatological indications for the use of isotretinoin beyond acne. Forbat E; Ali FR; Al-Niaimi F J Dermatolog Treat; 2018 Nov; 29(7):698-705. PubMed ID: 29480033 [TBL] [Abstract][Full Text] [Related]
16. Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. Rademaker M Australas J Dermatol; 2018 Feb; 59(1):26-30. PubMed ID: 27435665 [TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Marazzi P; Boorman GC; Donald AE; Davies HD J Dermatolog Treat; 2002 Sep; 13(3):111-7. PubMed ID: 12227873 [TBL] [Abstract][Full Text] [Related]